All resolutions concerning oncological medicinal products

Trastuzumab Emtansin (2) Kadcyla® Roche Pharma AG Oncological diseases ONCO Breast cancer 100% Hint for minor additional benefit
Neratinib Nerlynx® Pierre Fabre Pharma Oncological diseases ONCO Breast cancer 100% Indication for minor additional benefit
Gilteritinib XOSPATA® Astellas Pharma GmbH Oncological diseases ONCO ORPHAN Acute myeloid leukemia (AML) 100% Indication for considerable additional benefit
Avelumab (2) Bavencio® Merck Serono GmbH / Pfizer Pharma GmbH Oncological diseases ONCO Renal cell carcinoma 23% Indication for considerable additional benefit
Pembrolizumab (13) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Squamous cell carcinoma (SCC), Head and neck cancer 100% Hint for minor additional benefit
Pembrolizumab (12) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Squamous cell carcinoma (SCC), Head and neck cancer 100% Indication for considerable additional benefit
Pembrolizumab (11) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 23% Hint for considerable additional benefit
Niraparib (2, reassessment >€50m) Zejula® TESARO Bio Germany GmbH Oncological diseases ONCO ORPHAN Ovarian carcinoma / fallopian tube carcinoma / peritoneal carcinoma 100% no additional benefit
Larotrectinib Vitrakvi® Bayer Vital GmbH Oncological diseases ONCO Solid tumors, NTRK gene fusion 100% no additional benefit
Atezolizumab (4) Tecentriq® Roche Pharma AG Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Atezolizumab (6) Tecentriq® Roche Pharma AG Oncological diseases ONCO Breast cancer 100% Indication for non-quantifiable additional benefit
Atezolizumab (5) Tecentriq® Roche Pharma AG Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Trifluridin / Tipiracil (2) Lonsurf® Servier Deutschland GmbH Oncological diseases ONCO Stomach cancer 100% Hint for minor additional benefit
Atezolizumab (7) Tecentriq® Roche Pharma AG Oncological diseases ONCO Small cell lung carcinoma (ES-SCLC) 100% Indication for minor additional benefit
Elotuzumab (2) Empliciti® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Multiple myeloma (MM) 100% Indication for considerable additional benefit
Ramucirumab (5) Cyramza® Lilly Deutschland GmbH Oncological diseases ONCO ORPHAN Hepatocellular carcinoma (HC) 100% Proof of minor additional benefit
Ibrutinib (5) Imbruvica® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Chronic lymphocytic leukemia (CLL) 26% Indication for minor additional benefit
Ibrutinib (6) Imbruvica® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Waldenstroem's macroglobulinemia 100% no additional benefit
Ropeginterferon alfa-2b Besremi® AOP Orphan Pharmaceuticals AG Oncological diseases ONCO Polycythemia vera 100% no additional benefit
Cemiplimab Libtayo® Sanofi-Aventis Deutschland GmbH Oncological diseases ONCO Squamous cell carcinoma (SCC) 100% no additional benefit
Olaparib (3) Lynparza® AstraZeneca GmbH Oncological diseases ONCO Breast cancer 100% Indication for minor additional benefit
Olaparib (4) Lynparza® AstraZeneca GmbH Oncological diseases ONCO Ovarian carcinoma / peritoneal carcinoma 100% no additional benefit
Lorlatinib Lorviqua® Pfizer Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Pomalidomid (3) Imnovid® Celgene GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% no additional benefit
Dacomitinib Vizimpro® Pfizer Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Radium-223-dichlorid (2, reassessment) Xofigo® Bayer Vital GmbH Oncological diseases ONCO Prostate carcinoma (CRPC) 100% no additional benefit
Pembrolizumab (10) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 71% Indication for considerable additional benefit
Pembrolizumab (9) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% Indication for non-quantifiable additional benefit
Rucaparib Rubraca® Clovis Oncology Germany GmbH Oncological diseases ONCO Ovarian carcinoma 100% no additional benefit
Brentuximab Vedotin (4) Adcetris® Takeda Pharma GmbH Oncological diseases ONCO ORPHAN Hodgkin lymphoma (CD30+) 100% Hint for non-quantifiable additional benefit
Rucaparib (2) Rubraca® Clovis Oncology Germany GmbH Oncological diseases ONCO Ovarian carcinoma 100% no additional benefit
Pembrolizumab (8) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Melanoma, adjuvant therapy 100% Hint for non-quantifiable additional benefit
Blinatumomab (3) Blincyto® Amgen GmbH Oncological diseases ONCO ORPHAN Acute lymphoblastic leukemia (ALL) 100% Hint for non-quantifiable additional benefit
Blinatumomab (4) Blincyto® Amgen GmbH Oncological diseases ONCO ORPHAN Acute lymphoblastic leukemia (ALL) 100% non-quantifiable additional benefit
Lenvatinib (4, reassessment) Lenvima® Eisai GmbH Oncological diseases ONCO Thyroid cancer (DTC) 100% no additional benefit
Ipilimumab (5) Yervoy® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Renal cell carcinoma (RCC) 100% Hint for considerable additional benefit
Nivolumab (12) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Renal cell carcinoma (RCC) 100% Hint for considerable additional benefit
Apalutamid Erleada® Janssen-Cilag GmbH Oncological diseases ONCO Prostate carcinoma (HSPC) 100% Indication for minor additional benefit
Brigatinib Alunbrig® Takeda Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Ribociclib (2) Kisqali® Novartis Pharma GmbH Oncological diseases ONCO Breast cancer 100% no additional benefit
Pembrolizumab (7, reassessment) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Urothelial carcinoma (UC) 100% no additional benefit
Atezolizumab (3, reassessment) Tecentriq® Roche Pharma AG Oncological diseases ONCO Urothelial carcinoma (UC) 100% no additional benefit
Cabozantinib (5) Cabometyx® Ipsen Pharma GmbH Oncological diseases ONCO Hepatic cellular carcinoma (HCC) 100% Indication for minor additional benefit
Enzalutamid (3) Xtandi® Astellas Pharma GmbH Oncological diseases ONCO Prostate carcinoma (CRPC) 100% no additional benefit
Venetoclax (2) Venclyxto® AbbVie Deutschland GmbH Oncological diseases ONCO Chronic lymphocytic leucemia (CLL) 37% Hint for minor additional benefit
Venetoclax (3, reassessment) Venclyxto® AbbVie Deutschland GmbH Oncological diseases ONCO Chronic lymphocytic leucemia (CLL) 100% no additional benefit
Axicabtagen-Ciloleucel (2) Yescarta® Kite, Gilead company Oncological diseases ONCO ORPHAN Diffuse large B-cell lymphoma (DLBCL) 100% Hint for non-quantifiable additional benefit
Axicabtagen-Ciloleucel Yescarta® Kite, Gilead company Oncological diseases ONCO ORPHAN Primary medial major cell B-lymphoma (PMBCL) 100% Hint for non-quantifiable additional benefit
Abemaciclib (2) Verzenios® Lilly Deutschland GmbH Oncological diseases ONCO Breast cancer (HER2-) in combination with Fulvestrant 100% no additional benefit
Abemaciclib Verzenios® Lilly Deutschland GmbH Oncological diseases ONCO Breast cancer (HER2-) 100% no additional benefit
Pembrolizumab (6) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Head and neck cancer 100% no additional benefit
Durvalumab Imfinzi® AstraZeneca GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% Indication for considerable additional benefit
Trametinib (3) Mekinist® Novartis Pharma GmbH Oncological diseases ONCO Melanoma, adjuvant therapy 100% Hint for considerable additional benefit
Dabrafenib (4) Tafinlar® Novartis Pharma GmbH Oncological diseases ONCO Melanoma, adjuvant therapy 100% Hint for considerable additional benefit
Binimetinib Mektovi® Pierre Fabre Pharma GmbH Oncological diseases ONCO Melanoma 100% no additional benefit
Encorafenib Braftovi® Pierre Fabre Pharma GmbH Oncological diseases ONCO Melanoma 100% no additional benefit
Palbociclib (2, reassessment) Ibrance® Pfizer Pharma GmbH Oncological diseases ONCO Breast cancer 100% no additional benefit
Lenvatinib (3) Lenvima® Eisai GmbH Oncological diseases ONCO Hepatocellular carcinoma (HC) 100% no additional benefit
Daunorubicin / Cytarabin Vyxeos® Jazz Pharmaceuticals Oncological diseases ONCO ORPHAN Acute myeloid leukemia (AML) 100% Hint for considerable additional benefit
Daratumumab (3) Darzalex® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% Indication for considerable additional benefit
Tisagenlecleucel Kymriah® Novartis Pharma GmbH Oncological diseases ONCO ORPHAN Diffuse large B-cell lymphoma (DLBCL) 100% non-quantifiable additional benefit
Tisagenlecleucel (2) Kymriah® Novartis Pharma GmbH Oncological diseases ONCO ORPHAN Acute lymphoblastic leukemia (ALL) 100% Indication for non-quantifiable additional benefit
Nivolumab (11) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma, adjuvant therapy 100% Indication for non-quantifiable additional benefit
Gemtuzumab Ozogamicin Mylotarg® Pfizer Pharma GmbH Oncological diseases ONCO ORPHAN Acute myeloid leukemia (AML) 100% non-quantifiable additional benefit
Bosutinib (3, reassessment) Bosulif® Pfizer Pharma GmbH Oncological diseases ONCO Chronic myeloid leukemia (CML) 100% no additional benefit
Osimertinib (3) Tagrisso® AstraZeneca GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 84% Indication for considerable additional benefit
Ipilimumab (4) Yervoy® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 85% no additional benefit
Nivolumab (10, reassessment) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 100% Hint for less benefit
Pertuzumab (3) Perjeta® Roche Pharma AG Oncological diseases ONCO Breast cancer 100% Hint for minor additional benefit
Olaparib (2, reassessment) Lynparza® AstraZeneca GmbH Oncological diseases ONCO Ovarian carcinoma 100% Indication for minor additional benefit
Cabozantinib (4) Cabometyx® Ipsen Pharma GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 100% no additional benefit
Bosutinib (2) Bosulif® Pfizer Pharma GmbH Oncological diseases ONCO Chronic myeloid leukemia (CML) 100% no additional benefit
Carfilzomib (3, reassessment >€50m) Kyprolis® Amgen GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% Indication for considerable additional benefit
Sonidegib Odomzo® Sun Pharmaceuticals Germany GmbH Oncological diseases ONCO Basal cell carcinoma (1aBCC) 100% no additional benefit
Ipilimumab (3) Yervoy® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 100% no additional benefit
Brentuximab Vedotin (3) Adcetris® Takeda Pharma GmbH Oncological diseases ONCO ORPHAN Non-Hodgkin lymphoma (CD30+) 100% minor additional benefit
Alectinib (2) Alecensa® Roche Pharma AG Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 100% Indication for non-quantifiable additional benefit
Abirateronacetat (3) Zytiga® Janssen-Cilag GmbH Oncological diseases ONCO Prostate carcinoma (HSPC) 100% Hint for considerable additional benefit
Niraparib Zejula® TESARO Bio Germany GmbH Oncological diseases ONCO ORPHAN Ovarian carcinoma 100% non-quantifiable additional benefit
Tivozanib Fotivda® EUSA Pharma GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 100% no additional benefit
Cabozantinib (3, reassessment) Cabometyx® Ipsen Pharma GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 100% Hint for minor additional benefit
Midostaurin Rydapt® Novartis Pharma GmbH Oncological diseases ONCO ORPHAN Acute myeloid leukemia (AML), Mastocytosis (ASM) 100% non-quantifiable additional benefit
Obinutuzumab (3) Gazyvaro® Roche Pharma AG Oncological diseases ONCO ORPHAN Follicular lymphoma (FL) 100% non-quantifiable additional benefit
Ribociclib Kisqali® Novartis Pharma GmbH Oncological diseases ONCO Breast cancer (HR+ / HER2-) 100% no additional benefit
Pembrolizumab (5) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Urothelial carcinoma (UC) 61% Hint for considerable additional benefit
Atezolizumab Tecentriq® Roche Pharma AG Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 40% Hint for considerable additional benefit
Atezolizumab (2) Tecentriq® Roche Pharma AG Oncological diseases ONCO Urothelial carcinoma (UC) 61% Indication for minor additional benefit
Avelumab Bavencio® Merck Serono GmbH / Pfizer Pharma GmbH Oncological diseases ONCO ORPHAN Merkel cell carcinoma (MCC) 70% Hint for non-quantifiable additional benefit
Daratumumab (2, reassessment >€50m) Darzalex® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 72% Hint for considerable additional benefit
Ceritinib (3) Zykadia® Novartis Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 100% no additional benefit
Inotuzumab Ozogamicin Besponsa® Pfizer Pharma GmbH Oncological diseases ONCO ORPHAN Acute lymphoblastic leukemia (ALL) 100% minor additional benefit
Nivolumab (9) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Urothelial carcinoma (UC) 100% no additional benefit
Blinatumomab (2, reassessment) Blincyto® Amgen GmbH Oncological diseases ONCO ORPHAN Acute lymphoblastic leukemia (ALL) 100% considerable additional benefit
Nivolumab (8, reassessment) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 100% no additional benefit
Nivolumab (7) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Squamous cell carcinoma (SCC), Head and neck cancer 77% Indication for considerable additional benefit
Pembrolizumab (4) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Hodgkin-Lymphoma (HL) 100% no additional benefit
Dabrafenib (3) Tafinlar® Novartis Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (BRAF-V600+ NSCLC) 100% no additional benefit
Trametinib (2) Mekinist® Novartis Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (BRAF-V600+ NSCLC) 100% no additional benefit
Alectinib Alecensa® Roche Pharma AG Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 81% Indication for minor additional benefit
Osimertinib (2, reassessment) Tagrisso® AstraZeneca GmbH Oncological diseases ONCO Non-small cell lung carcinoma (T790M+ NSCLC) 100% Indication for considerable additional benefit
Axitinib (2, reassessment) Inlyta® Pfizer Pharma GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 0.3% Indication for minor additional benefit
Pembrolizumab (3) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% Hint for considerable additional benefit
Vandetanib (3) Caprelsa® Genzyme GmbH Oncological diseases ONCO Medullary thyroid cancer (MTC) 100% Indication for non-quantifiable additional benefit
Ixazomib Ninlaro® Takeda Pharma GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% non-quantifiable additional benefit
Nivolumab (6) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Hodgkin-Lymphoma (HL) 100% no additional benefit
Venetoclax Venclyxto® AbbVie Deutschland GmbH & Co. KG Oncological diseases ONCO ORPHAN Chronic lymphocytic leukemia (CLL) 100% non-quantifiable additional benefit
Palbociclib Ibrance® Pfizer Pharma GmbH Oncological diseases ONCO Breast cancer 100% no additional benefit
Olaratumab Lartruvo® Lilly Deutschland GmbH Oncological diseases ONCO ORPHAN Soft tissue sarcoma 100% considerable additional benefit
Cabozantinib (2) Cabometyx® Ipsen Pharma GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 100% Indication for non-quantifiable additional benefit
Ceritinib (2, reassessment) Zykadia® Novartis Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 81% Indication for considerable additional benefit
Crizotinib (4) Xalkori® Pfizer Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Lenvatinib (2) Kisplyx® Eisai GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 100% Indication for minor additional benefit
Idelalisib (3) Zydelig® Gilead Sciences GmbH Oncological diseases ONCO Chronic lymphocytic leukemia (CLL) 0.4% non-quantifiable additional benefit
Ibrutinib (4) Imbruvica® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Chronic lymphocytic leukemia (CLL) 50% Indication for considerable additional benefit
Pembrolizumab (2) Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 40% Hint for considerable additional benefit
Trifluridin / Tipiracil Lonsurf® Servier Deutschland GmbH Oncological diseases ONCO Metastatic colorectal carcinoma (mCRC) 100% Indication for minor additional benefit
Brentuximab Vedotin (2) Adcetris® Takeda Pharma GmbH Oncological diseases ONCO ORPHAN Hodgkin lymphoma (CD30+) 100% non-quantifiable additional benefit
Carfilzomib (2) Kyprolis® Amgen GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% minor additional benefit
Ibrutinib (3) Imbruvica® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Chronic lymphocytic leukemia (CLL) 100% no additional benefit
Crizotinib (3, reassessment) Xalkori® Pfizer Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 71% Indication for considerable additional benefit
Obinutuzumab (2) Gazyvaro® Roche Pharma AG Oncological diseases ONCO ORPHAN Follicular lymphoma (FL) 100% non-quantifiable additional benefit
Nivolumab (5) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 100% no additional benefit
Talimogen laherparepvec Imlygic® Amgen GmbH Oncological diseases ONCO Melanoma 100% no additional benefit
Eribulin (3) Halaven® Eisai GmbH Oncological diseases ONCO Liposarcoma 50% Indication for considerable additional benefit
Elotuzumab Empliciti® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Multiple myeloma (MM) 100% Indication for minor additional benefit
Daratumumab Darzalex® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% non-quantifiable additional benefit
Ramucirumab (4, reassessment) Cyramza® Lilly Deutschland GmbH Oncological diseases ONCO Advanced gastric cancer (adenocarcinoma) 50% Indication for minor additional benefit
Afatinib (3) Giotrif® Boehringer Ingelheim Pharma GmbH & Co. KG Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Nivolumab (4) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Renal cell carcinoma (RCC) 92% Hint for considerable additional benefit
Nivolumab (3) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 40% Hint for considerable additional benefit
Osimertinib Tagrisso® AstraZeneca GmbH Oncological diseases ONCO Non-small cell lung carcinoma (T790M+ NSCLC) 100% no additional benefit
Necitumumab Portrazza® Lilly Deutschland GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Idelalisib (2, reassessment) Zydelig® Gilead Sciences GmbH Oncological diseases ONCO Chronic lymphocytic leukemia (CLL) 24% Indication for non-quantifiable additional benefit
Ramucirumab (3) Cyramza® Lilly Deutschland GmbH Oncological diseases ONCO Metastatic colorectal carcinoma (mCRC) 100% no additional benefit
Ramucirumab (2) Cyramza® Lilly Deutschland GmbH Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% no additional benefit
Vismodegib (2, reassessment) Erivedge® Roche Pharma AG Oncological diseases ONCO Basal cell carcinoma (smBCC, laBCC) 95% Indication for minor additional benefit
Ibrutinib (2, reassessment >€50m) Imbruvica® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Mantle cell lymphoma (MCL), Chronic lymphatic leukemia (CLL) 4% Hint for considerable additional benefit
Crizotinib (2) Xalkori® Pfizer Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 100% Indication for considerable additional benefit
Blinatumomab Blincyto® Amgen GmbH Oncological diseases ONCO ORPHAN Acute lymphoblastic leukemia (ALL) 100% non-quantifiable additional benefit
Carfilzomib Kyprolis® Amgen GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% non-quantifiable additional benefit
Cobimetinib Cotellic® Roche Pharma AG Oncological diseases ONCO Melanoma (BRAF-V600+) 100% Hint for considerable additional benefit
Trametinib Mekinist® Novartis Pharma GmbH Oncological diseases ONCO Melanoma 50% Hint for considerable additional benefit
Regorafenib (3, reassessment) Stivarga® Bayer Vital GmbH Oncological diseases ONCO Metastatic colorectal carcinoma (mCRC) 100% no additional benefit
Pomalidomid (2, reassessment >€50m) Imnovid® Celgene GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 50% Indication for considerable additional benefit
Panobinostat Farydak® Novartis Pharma GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% non-quantifiable additional benefit
Dabrafenib (2) Tafinlar® Novartis Pharma GmbH Oncological diseases ONCO Melanoma (BRAF-V600+) 100% Hint for considerable additional benefit
Pertuzumab (2) Perjeta® Roche Pharma AG Oncological diseases ONCO Breast cancer 100% no additional benefit
Pembrolizumab Keytruda® MSD Sharp & Dohme GmbH Oncological diseases ONCO Melanoma 71% Hint for considerable additional benefit
Nivolumab (2) Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 87% Hint for considerable additional benefit
Nivolumab Opdivo® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 15% Hint for considerable additional benefit
Lenvatinib Lenvima® Eisai GmbH Oncological diseases ONCO ORPHAN Differentiated thyroid cancer (DTC) 100% non-quantifiable additional benefit
Ceritinib Zykadia® Novartis Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 100% no additional benefit
Olaparib Lynparza® AstraZeneca GmbH Oncological diseases ONCO ORPHAN Ovarian carcinoma 100% non-quantifiable additional benefit
Afatinib (2, reassessment) Giotrif® Boehringer Ingelheim Pharma GmbH & Co. KG Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 42% Hint for major additional benefit
Ruxolitinib (3) Jakavi® Novartis Pharma GmbH Oncological diseases ONCO Polycythaemia vera 100% Indication for considerable additional benefit
Ramucirumab Cyramza® Lilly Deutschland GmbH Oncological diseases ONCO ORPHAN Advanced gastric cancer (adenocarcinoma) 100% Hint for minor additional benefit
Nintedanib Vargatef® Boehringer Ingelheim Pharma GmbH & Co. KG Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 100% Hint for minor additional benefit
Enzalutamid (2) Xtandi® Astellas Pharma GmbH Oncological diseases ONCO Prostate carcinoma (CRPC) 100% Hint for considerable additional benefit
Ibrutinib Imbruvica® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Mantle cell lymphoma (MCL), Chronic lymphatic leukemia (CLL) 4% Hint for non-quantifiable additional benefit
Sipuleucel-T Provenge® Dendreon UK Limited Oncological diseases ONCO Prostate carcinoma (CRPC) 100% Indication for non-quantifiable additional benefit
Idelalisib Zydelig® Gilead Sciences GmbH Oncological diseases ONCO Chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) 20% Indication for non-quantifiable additional benefit
Regorafenib (2) Stivarga® Bayer Vital GmbH Oncological diseases ONCO Gastrointestinal stoma tumor (GIST) 100% no additional benefit
Obinutuzumab Gazyvaro® Roche Pharma AG Oncological diseases ONCO ORPHAN Chronic lymphocytic leukemia (CLL) 100% Hint for non-quantifiable additional benefit
Cabozantinib Cometriq® Swedish Orphan Biovitrum GmbH Oncological diseases ONCO ORPHAN Medullary thyroid cancer (MTC) 100% minor additional benefit
Eribulin (2, reassessment) Halaven® Eisai GmbH Oncological diseases ONCO Breast cancer 75% Indication for considerable additional benefit
Siltuximab Sylvant® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Multicentric Castleman Disease (MCD) 100% non-quantifiable additional benefit
Ruxolitinib (2, reassessment >€50m) Jakavi® Novartis Pharma GmbH Oncological diseases ONCO ORPHAN Chronic myeloproliferative disease (CML) 100% Indication for considerable additional benefit
Trastuzumab Emtansin Kadcyla® Roche Pharma AG Oncological diseases ONCO Breast cancer (HER2+) 72% Hint for considerable additional benefit
Radium-223-dichlorid Xofigo® Bayer Vital GmbH Oncological diseases ONCO Prostate carcinoma (mCRPC) 78% Hint for considerable additional benefit
Ipilimumab (2) Yervoy® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 100% no additional benefit
Dabrafenib Tafinlar® GlaxoSmithKline GmbH & Co. KG Oncological diseases ONCO Melanoma (BRAF-V600+) 100% no additional benefit
Regorafenib Stivarga® Bayer Vital GmbH Oncological diseases ONCO Metastatic colorectal carcinoma (mCRC) 100% Indication for minor additional benefit
Vemurafenib (2, reassessment) Zelboraf® Roche Pharma AG Oncological diseases ONCO Melanoma (BRAF-V600+) 100% Hint for considerable additional benefit
Pomalidomid Imnovid® Celgene GmbH Oncological diseases ONCO ORPHAN Multiple myeloma (MM) 100% considerable additional benefit
Enzalutamid Xtandi® Astellas Pharma GmbH Oncological diseases ONCO Prostate carcinoma (CRPC) 100% Hint for considerable additional benefit
Vismodegib Erivedge® Roche Pharma AG Oncological diseases ONCO Basal cell carcinoma (smBCC, laBCC) 95% Indication for minor additional benefit
Ponatinib Iclusig® ARIAD Pharmaceuticals (Germany) GmbH Oncological diseases ONCO ORPHAN Chronic myeloic leukemia (CML), Acute lymphoblastic leukemia (Ph+ ALL) 100% Hint for non-quantifiable additional benefit
Bosutinib Bosulif® Pfizer Pharma GmbH Oncological diseases ONCO ORPHAN Chronic myeloid leukemia (CML) 100% Hint for non-quantifiable additional benefit
Pertuzumab Perjeta® Roche Pharma AG Oncological diseases ONCO Breast cancer (HER2+) 33% Indication for considerable additional benefit
Vandetanib (2, reassessment) Caprelsa® AstraZeneca GmbH Oncological diseases ONCO Medullary thyroid cancer (MTC) 100% Indication for minor additional benefit
Aflibercept (2, Zaltrap®) Zaltrap® Sanofi-Aventis Deutschland GmbH Oncological diseases ONCO Metastatic colorectal carcinoma (mCRC) 100% Hint for minor additional benefit
Pixantron Pixuvri® CTI Life Sciences Ltd. Oncological diseases ONCO Non-Hodgkin lymphoma (NHL) 100% no additional benefit
Brentuximab Vedotin Adcetris® Takeda Pharma Vertrieb GmbH & Co. KG Oncological diseases ONCO ORPHAN Hodgkin lymphoma (CD30+), Anaplastic large-cell lymphoma 68% Hint for non-quantifiable additional benefit
Decitabin Dacogen® Janssen-Cilag GmbH Oncological diseases ONCO ORPHAN Acute myeloid leukemia (AML) 100% minor additional benefit
Crizotinib Xalkori® Pfizer Pharma GmbH Oncological diseases ONCO Non-small cell lung carcinoma (ALK+ NSCLC) 71% Indication for considerable additional benefit
Ruxolitinib Jakavi® Novartis Pharma GmbH Oncological diseases ONCO ORPHAN Chronic myeloproliferative diseases (CML) 100% Hint for minor additional benefit
Axitinib Inlyta® Pfizer Pharma GmbH Oncological diseases ONCO Renal cell carcinoma (RCC) 0.7% Hint for minor additional benefit
Tegafur / Gimeracil / Oteracil Teysuno® Nordic Pharma GmbH Oncological diseases ONCO Advanced gastric cancer (adenocarcinoma) 100% no additional benefit
Vemurafenib Zelboraf® Roche Pharma AG Oncological diseases ONCO Melanoma (BRAF-V600+) 100% Hint for considerable additional benefit
Vandetanib Caprelsa® AstraZeneca GmbH Oncological diseases ONCO Medullary thyroid cancer (MTC) 100% no additional benefit
Ipilimumab Yervoy® Bristol-Myers Squibb GmbH & Co. KGaA Oncological diseases ONCO Melanoma 100% Hint for considerable additional benefit
Abirateronacetat (2) Zytiga® Janssen-Cilag GmbH Oncological diseases ONCO Prostate carcinoma 100% Hint for considerable additional benefit
Eribulin Halaven® Eisai GmbH Oncological diseases ONCO Breast cancer 80% Indication for minor additional benefit
Afatinib Giotrif® Boehringer Ingelheim Pharma GmbH & Co. KG Oncological diseases ONCO Non-small cell lung carcinoma (NSCLC) 44% Hint for considerable additional benefit
Cabazitaxel Jevtana® Sanofi-Aventis Deutschland GmbH Oncological diseases ONCO Prostate carcinoma 85% Hint for minor additional benefit
Abirateronacetat Zytiga® Janssen-Cilag GmbH Oncological diseases ONCO Prostate carcinoma 85% Hint for considerable additional benefit